Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Stock News Trends Just Put (Nasdaq: MODD) At The Top Of
This Morning’s Watchlist—Wednesday, July 1, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up MODD While It’s Still Early… July 1, 2026 Dear Reader, When an emerging medical-device company moves from commercial launch to confirmed real-world use, it often marks the most telling milestone in its history—the moment a story becomes a business. That is exactly the type of development we're highlighting today. Combined with a large target market and a product designed to address a longstanding gap in diabetes care, this is a story we believe deserves a closer look. Modular Medical, Inc. (Nasdaq: MODD) is a diabetes technology company that just reached its most significant milestone yet. Yesterday, on June 30, 2026, the company announced that its first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings—delivering actual insulin therapy outside of a clinical trial environment for the first time. According to MODD, the company will now begin collecting real-world utilization data and user feedback to support broader adoption and continued product deployment optimization, marking its transition from a commercial-stage business with a cleared product to a commercial-stage business with patients actually on it. The milestone follows just six days behind the company's announcement that Pivot™ became commercially available in the United States on June 24, 2026, following FDA 510(k) clearance received in April—and just weeks after the launch of PivotPump.com. In other words, MODD has now moved through the full sequence in a matter of weeks: regulatory clearance, commercial availability, and confirmed real-world patient use. According to the company, broader commercial expansion activities are expected to begin in late 2026, with the rollout starting through select high-volume endocrinology practices before expanding into multiple metropolitan markets. What makes this story particularly compelling is the patient population MODD is targeting. According to the company, approximately 4.8M Americans require daily insulin, yet only about 20% currently use an insulin pump. Pivot was developed specifically for adults who remain on multiple daily injections because of cost, complexity, or usability barriers associated with traditional pump systems—a group MODD refers to as the "almost-pumper" population. The company estimates this segment represents a $3B market within the broader diabetes technology industry. MODD also notes that Pivot is only the second fully electronic, tubeless insulin pump currently available in the United States. Add in a founder who previously founded Tandem Diabetes Care and designed the widely recognized T:Slim insulin pump, and MODD enters this new phase with both a differentiated product now confirmed in patient use and leadership deeply rooted in insulin delivery technology. These are only some of the reasons why MODD is topping our watchlist this morning—Wednesday, July 1, 2026. 
Keep in mind, MODD has less than 2.5M shares listed as available to the public. When companies have public floats this small, the potential exists for big moves if demand begins to shift. The founder behind MODD has a background closely tied to one of the most recognized names in diabetes technology. Paul DiPerna previously founded Tandem Diabetes Care in 2005 and invented and designed its T:Slim insulin pump—one of the most recognized names in the diabetes technology space. He applied that same engineering discipline to MODD, this time with a focus on eliminating the tradeoffs that have kept a large portion of insulin-dependent patients on injections rather than pump therapy. Beyond the U.S., MODD is targeting CE Mark approval for European markets, with a timeline of Q4 2026 or Q1 2027. That international pathway represents a second wave of addressable patients behind the U.S. commercial launch—and it's already in motion. Here's what you need to know about MODD. About Modular Medical, Inc. (Nasdaq: MODD)
Modular Medical, Inc. is a San Diego-based development-stage medical device company focused on the design, development, and commercialization of next-generation insulin delivery technology. Its mission, stated plainly, is to provide "diabetes care for the rest of us"—expanding access to the highest standard of glycemic control beyond what the company calls "superusers" of traditional pump systems. The company's flagship product is the Pivot™ insulin delivery system—the first two-part tubeless patch pump designed for adults with type 1 or type 2 diabetes. The Pivot combines a reusable controller with a disposable cartridge module, giving patients a tubeless design, 3 mL removable reservoir, disposable battery, smartphone-based dosing and monitoring, and an on-device bolus button for dosing without a phone. 
See the Pivot™ Insulin Delivery System by clicking here. In plain English, it was built to reduce the cost, complexity, and wearability issues that have kept many insulin-dependent adults on daily injections instead of pump therapy. According to Modular Medical, Pivot™ was developed to simplify diabetes management for adults who have remained on multiple daily injections rather than traditional insulin pumps. The company says many existing pump systems require a greater time commitment and learning curve than some patients are willing to accept. Founder Paul DiPerna has explained that, after helping develop one of the industry's more sophisticated insulin pumps, it became clear that many insulin-dependent adults were being left behind. 
Paul DiPerna explains why Pivot™ was designed to simplify insulin pump therapy for adults still relying on daily injections. Watch the video here. Rather than building another highly complex system, Modular Medical focused on reducing barriers such as cost, usability, lifestyle disruption, and the time required to learn pump therapy. The result is Pivot—a tubeless insulin patch pump designed to be easier to wear, simpler to operate, and capable of automatically capturing treatment information that can be shared with healthcare providers. According to the company, its mission is to reduce the burden of diabetes care while expanding access to pump technology for the large population of adults who continue to rely on daily injections. Modular Medical's scalable, low-cost manufacturing platform is designed to address this gap at accessible price points, while a software roadmap including variable bolus, improved alarms, and ACE/AID compatibility is already in development. The company filed for FDA 510(k) clearance for the Pivot in November 2025 and received clearance on April 9, 2026. It is also pursuing CE Mark approval for European markets, targeting Q4 2026 or Q1 2027, and has retained BSI Group as its notified body for that process. Diabetes Technology and Insulin Delivery
The diabetes technology sector sits at the intersection of two converging forces: a growing global disease burden and a persistent under-penetration of pump-based insulin therapy. Together, they define the structural opportunity that MODD is positioning to capture. Consider the base figures. There are approximately 4.8M Americans who require daily insulin. Of those, the company notes that only roughly 20% currently use an insulin pump—meaning some 3.8M insulin-dependent adults in the U.S. alone remain on multiple daily injections (MDI). The global insulin pump market is sized at approximately $8B, according to data cited in Modular Medical's own filings. The subsegment specifically targeted by Pivot—adult "almost-pumpers"—represents what the company has characterized as a $3B addressable market. 
The reason for that gap between disease burden and device adoption is well-documented: traditional insulin pumps are expensive, technically demanding, and often designed for younger, tech-comfortable patients. The market structure has historically favored established players like Medtronic, Insulet (Omnipod), and Tandem Diabetes Care—none of which have specifically engineered their flagship products around simplicity and price accessibility for the broader adult MDI population. MODD's Pivot is architecturally different. It is designed from the ground up around the specific barriers that keep most insulin-dependent adults on injections: cost, tube complexity, wearability, and the learning curve. The two-part removable design—reusable controller, disposable cartridge—creates a recurring revenue model while keeping per-unit costs accessible. The smartphone-first bolus architecture removes the need for a dedicated handheld controller, reducing both device cost and patient complexity. The broader diabetes device sector is expanding rapidly. The global insulin pump market, while already large, is benefiting from increasing type 2 diabetes adoption—a historically underpenetrated but rapidly growing segment for device-based therapy. Automated insulin delivery (AID) features, which MODD has on its software roadmap, represent the next major frontier in clinical differentiation. If Pivot reaches AID compatibility, its addressable market expands further still. Recent Milestones
First Patients Now Active on Pivot™ — June 30, 2026
MODD announced that its first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. According to the company, this marks its transition into a commercial-stage business with patients actively receiving insulin therapy on the device. MODD will now begin collecting real-world utilization data and user feedback to support broader adoption and continued deployment optimization. Commercial Availability — June 24, 2026
MODD announced that its Pivot™ tubeless insulin patch pump is now commercially available in the United States following FDA 510(k) clearance received in April. According to the company, first shipments are beginning this week, marking the start of real-world patient use and MODD's transition from a development-stage medical device company to a commercial-stage business. The company also noted that Pivot is only the second fully electronic, tubeless insulin pump currently available in the United States. PivotPump.com Launch — June 4, 2026
MODD launched PivotPump.com, a patient-focused website designed to help individuals learn about Pivot™ and explore a simpler path to insulin pump therapy while reaffirming its commercialization plans. FDA 510(k) Clearance — April 9, 2026
MODD received FDA 510(k) clearance for Pivot™, clearing the path for commercial sales in the United States. The clearance represented a major regulatory milestone ahead of commercialization. 7 Reasons Why MODD is At The Top Of Our Watchlist This Morning—Wednesday, July 1, 2026…
1. Patient Use: Modular Medical has confirmed that MODD’s first patients are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. 2. FDA Cleared: After receiving FDA 510(k) clearance in April 2026, MODD moved Pivot™ into U.S. commercial availability by June 24, 2026. 3. Tiny Float: With fewer than 2.5M shares listed as available to the public, MODD has a small float that could contribute to volatility if demand shifts. 4. Large Need: According to the company, MODD is targeting adults among the roughly 4.8M Americans who require daily insulin but do not broadly use pump therapy. 5. Founder Pedigree: Founder Paul DiPerna previously founded Tandem Diabetes Care and invented and designed the T:Slim insulin pump, giving MODD leadership experience in insulin delivery technology. 6. Tubeless Design: Pivot™ makes MODD one of only two fully electronic tubeless insulin pump options currently available in the U.S., according to the company. 7. Expansion Path: Beyond the U.S. rollout, MODD is pursuing CE Mark approval for European markets with a target timeline of Q4 2026 or Q1 2027. Pull Up MODD While It’s Still Early… 
With confirmed real-world patient use, recent FDA clearance followed by U.S. commercial availability, a public float of fewer than 2.5M shares, a large target patient population, experienced leadership, a differentiated tubeless insulin pump, and plans to expand into Europe, MODD has assembled a series of developments that continue to capture our attention. Taken together, these milestones help explain why Modular Medical remains at the top of our watchlist this morning. We have all eyes on MODD right now. Consider starting your own research on MODD while it’s still early. Also, keep a look out for my next update—it could be here any moment. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends |
No comments:
Post a Comment